Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Siegel, David; G Martin, Thomas; Nooka, A.; Donald Harvey, R.; Vij, Ravi; Niesvizky, Rubén; Badros, Ashraf; Jagannath, Sundar; McCulloch, Leanne; Rajangam, Kanya; Lonial, Sagar

doi:10.3324/haematol.2013.089334

Public

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Published in Haematologica • Aug 9, 2013

Authors:

David Siegel

Thomas G Martin

A. Nooka

Abstract

Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent carfilzomib have been analyzed for 526 patients with advanced multiple myeloma who took part in one of 4 phase II studies (PX-171-003-A0, PX...

Subject

Carfilzomib

Medicine

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!